Collection Periodical Articles [327/330] Books/Book Section [1/1] Conference Papers/Meeting Abstract [115/179] Siblings Winston C.Y. Yu [19/19] Ko-Jiunn Liu [85/98] Tsang-Wu Liu [119/125] Jieh-Yuan Liou(2003-2010) [3/3] Her-Shyong Shiah(1996-2012) [26/31] Shine-Gwo Shiah [51/54] Nai-Jung Chiang [82/94] Hui-Ju Mandy Ch'ang [39/44] Jang-Yang Chang [234/254] Kwang-Yu Chang [69/79] I-Shou Chang [103/106] Wun-Shaing Wayne Chang [52/53] Jeffrey Shu-Ming [89/91] Jacqueline Whang-Peng(1996-2007) [120/126] Neng-Yao Shih [37/43] Chia-Huei Lee [29/29] Alan Yueh-Luen Lee [48/49] Su-Fang Lin [32/32] Yi-Hsin Yang [41/42] Shih-Sheng Jiang [88/90] Che-Hung Shen [14/16] Wen-Chun Hung [88/88] Shuang-En Chuang [82/91] Kelvin Kun-Chih Tsai [32/34] Hui-Jen Tsai [66/71] Yung-Yeh Su [40/40] Jen-Liang Su [24/25] Ching-Chuan Kuo [71/76] Shang-Hung Chen [45/48] Jen-Yang Chen [72/72] Mei-Shya Chen(2002-2009) [1/1] Shih-Cheng Chen [2/2] Ya-Wen Chen [38/39] Tze-Sing Huang [55/55] Dau-Yang Huang [26/26] Chou-Chik George Ting(2000-2004) [5/5] Others [464/471] Ming Jacqueline Liu(1996-2007) [60/62] Mei-Ying Liu(2004-2006) [2/2] Cheng-Wen Wu(1996-2008) [53/55] Szu-Wen Tseng(1997-2007) [4/4] Kuan-Te Li(1997-2004) [4/6] Ching-Tai Lin(1999-2007) [5/5] Wen-Kuang Yang(1996-1999) [21/21] Chuan-Cheng Wang(1996-2003) [4/4] Shin-Hun P. Juang(1997-2004) [11/11] Tzung-Huang Jan(2000-2008) [2/2] Gi-Ming Lai(2004-2008) [41/47] Li-Jung Juan(2000-2006) [6/7] Jim-Ray Chen(2003-2007) [6/6] Yen-Ying Ma(1997-1999) [1/1] Chi-Ying F. Huang(2005-2007) [9/10] Community Statistics Item counts issued in 3 years:74(14.51%) Items With Fulltext:443(86.86%) Download counts of the item Download times greater than 0:443(100.00%) Download times greater than 100:426(96.16%) Total Bitstream Download Counts:178127(3.32%) Last Update: 2024-12-01 08:26 Top Upload Loading... Top Download Loading... Recent Submissions Pan-Asian adapted ESMO clinical pra... Nivolumab plus chemotherapy in pati... Survival of advanced/recurrent gast... Topiramate suppresses peri-infarct ... A phase 1 study of biweekly nab-pac... Plain language summary of the FOENI... Outcomes of post-immunotherapy dura... Durvalumab or placebo plus gemcitab... Impact of previous S-1 treatment on... Chromatin remodeling-related PRDM1 ...

Jump to a point in the index: (Choose year) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (Choose month) January February March April May June July August September October November December Or type in a year:

Ordering With Most Recent First Show Oldest First

Showing items 226-250 of 510. (21 Page(s) Totally) << < 5 6 7 8 9 10 11 12 13 14 > >> View [10|25|50] records per page

Date	Title	Relation
2017-09	Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37)	Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 671P.
2017-09	A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)	Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 617O.
2017-08	Overexpressed fatty acid synthase in gastrointestinal stromal tumors: Targeting a progression-associated metabolic driver enhances the antitumor effect of imatinib	Clinical Cancer Research. 2017 Aug;23(16):4908-4918.
2017-08	A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo	Cancer Chemotherapy and Pharmacology. 2017 Aug;80(2):307-315.
2017-07	A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17	Oncotarget. 2017 Jul;8(27):44121-44130.
2017-06-26	Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI +/- 5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy	Annals of Oncology. 2017 Jun 26;28(Suppl. 3):Abstract number PD - 018.
2017-06-26	CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) +/- 5-fluorouracil and leucovorin (5FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy	Annals of Oncology. 2017 Jun 26;28(Suppl. 3):Abstract number PD-017.
2017-05-04	Chemotherapy in the management of pancreatic cancer	Pancreatic Cancer: With Special Focus on Topical Issues and Surgical Techniques. 2017 May 4:387-419.
2017-05	Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: A Q-TWiST analysis	British Journal of Cancer. 2017 May;116(10):1247-1253.
2017-05	The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM	Journal of Clinical Oncology. 2017 May;35:Meeting Abstract e15795.
2017-05	A phase I dose escalation study of SCBO1A, a micro tubular inhibitor with vascular disrupting activity, in patients with advanced solid tumors refractory to standard therapy	Journal of Clinical Oncology. 2017 May;35(Suppl. 15):Meeting Abstract 2531.
2017-02	Nanoliposomal irinotecan in the clinical practice guideline for metastatic pancreatic cancer: Applicability to clinical situations	Journal of Clinical Oncology. 2017 Feb;35(6):689-690.
2017-02	The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21)	Journal of Pathology. 2017 Feb;241(3):420-433.
2017-02	Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells	Oncology Reports. 2017 Feb;37(2):969-978.
2017-02	A phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer	Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):417.
2017-02	Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPO	Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):303.
2017-02	Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial	Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):2.
2017-02	Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-FU/LV	Journal of Clinical Oncology. 2017 Feb;35(4):Meeting Abstract 293.
2017-01	Expressions of the CagA protein and CagA-signaling molecules predict H. pylori-dependence of early-stage gastric DLBCL	Blood. 2017 Jan;129(2):188-198.
2016-12	The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan	Asia-Pacific Journal of Clinical Oncology. 2016 Dec;12(4):396-402.
2016-12	Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study	Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 221PD.
2016-12	Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1	Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 242P.
2016-12	Sequential use of everolimus and sunitinib in treating WHO grade 1 and 2 pancreatic neuroendocrine tumors-retrospective multi-center study in Taiwan	Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 420P.
2016-11-21	A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors	BMC Cancer. 2016 Nov 21;16:Article number 907.
2016-11	Role of epigenetic regulator EHMT2 in the regulation of gemcitabine resistance in pancreatic cancer	Journal of Gastroenterology and Hepatology. 2016 Nov;31(Suppl. 3):245.

Showing items 226-250 of 510. (21 Page(s) Totally) << < 5 6 7 8 9 10 11 12 13 14 > >> View [10|25|50] records per page